Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency

Int J Gynecol Cancer. 2023 Jun 5;33(6):1008-1009. doi: 10.1136/ijgc-2023-004478.

Authors

Bradley J Monk^#¹, Robert L Coleman^#², Mansoor Raza Mirza³

Affiliations

¹ Virginia G Piper Cancer Center - Biltmore Cancer Center, Phoenix, Arizona, USA bmonk@gog.org.
² The US Oncology Network, The Woodlands, Texas, USA.
³ Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

^# Contributed equally.

PMID: 37024238
DOI: 10.1136/ijgc-2023-004478

No abstract available

Keywords: Ovarian Cancer.

MeSH terms

Carcinoma, Ovarian Epithelial / drug therapy
Female
Humans
Neoplasm Recurrence, Local / drug therapy
Ovarian Neoplasms* / drug therapy
Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use
United States / epidemiology
United States Food and Drug Administration

Substances

Poly(ADP-ribose) Polymerase Inhibitors